IL128850A - Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture - Google Patents

Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture

Info

Publication number
IL128850A
IL128850A IL12885097A IL12885097A IL128850A IL 128850 A IL128850 A IL 128850A IL 12885097 A IL12885097 A IL 12885097A IL 12885097 A IL12885097 A IL 12885097A IL 128850 A IL128850 A IL 128850A
Authority
IL
Israel
Prior art keywords
cyclobutyl
chlorophenyl
unsubstituted
humans
substituted
Prior art date
Application number
IL12885097A
Other languages
English (en)
Other versions
IL128850A0 (en
Original Assignee
Abott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abott Gmbh & Co Kg filed Critical Abott Gmbh & Co Kg
Publication of IL128850A0 publication Critical patent/IL128850A0/xx
Publication of IL128850A publication Critical patent/IL128850A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrotherapy Devices (AREA)
IL12885097A 1996-09-21 1997-09-15 Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture IL128850A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process
PCT/EP1997/005039 WO1998011884A1 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Publications (2)

Publication Number Publication Date
IL128850A0 IL128850A0 (en) 2000-01-31
IL128850A true IL128850A (en) 2003-07-31

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12885097A IL128850A (en) 1996-09-21 1997-09-15 Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture

Country Status (26)

Country Link
US (3) US6174925B1 (https=)
EP (1) EP0927028A1 (https=)
JP (1) JP2001503737A (https=)
KR (1) KR20000048501A (https=)
CN (1) CN1237905A (https=)
AU (1) AU724488B2 (https=)
BG (1) BG64473B1 (https=)
BR (1) BR9711517A (https=)
CA (1) CA2266401C (https=)
CZ (1) CZ93699A3 (https=)
GB (1) GB9619757D0 (https=)
HR (1) HRP970505A2 (https=)
HU (1) HUP9904026A3 (https=)
ID (1) ID18320A (https=)
IL (1) IL128850A (https=)
MY (1) MY116150A (https=)
NO (1) NO991358D0 (https=)
NZ (1) NZ334580A (https=)
PL (1) PL332305A1 (https=)
RU (1) RU2245709C2 (https=)
SK (1) SK31999A3 (https=)
TR (1) TR199900618T2 (https=)
TW (1) TW580385B (https=)
UA (1) UA64726C2 (https=)
WO (1) WO1998011884A1 (https=)
ZA (1) ZA978450B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
WO2000000195A1 (en) * 1998-06-30 2000-01-06 Takeda Chemical Industries, Ltd. Pharmaceutical composition for the treatment of diabetes
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
HK1040910B (en) * 1998-11-12 2009-06-26 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and metformin
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
CA2374260A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using sulfonyl thyromimetic compounds
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
JP4278652B2 (ja) * 2002-10-05 2009-06-17 ハンミ ファーム． シーオー．， エルティーディー． 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
PE20050335A1 (es) * 2003-08-07 2005-06-01 Sb Pharmco Inc Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
MXPA06004639A (es) * 2003-10-31 2006-06-27 Takeda Pharmaceutical Preparacion solida que comprende sensibilizador de insulina, secretagogo de insulina y ester de acidos grasos de polioxietileno sorbitano.
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
US20070203111A1 (en) 2006-01-06 2007-08-30 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
WO2008034142A2 (en) 2006-09-15 2008-03-20 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
US20110027458A1 (en) 2009-07-02 2011-02-03 Dexcom, Inc. Continuous analyte sensors and methods of making same
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
RU2642074C2 (ru) 2011-12-30 2018-01-24 Ревива Фармасьютикалс, Инк. Композиции, синтез и способы применения производных фенилциклоалкилметиламина
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
TW580385B (en) 2004-03-21
PL332305A1 (en) 1999-08-30
MY116150A (en) 2003-11-28
HRP970505A2 (en) 1998-08-31
TR199900618T2 (xx) 1999-06-21
CA2266401C (en) 2007-01-30
AU4774097A (en) 1998-04-14
IL128850A0 (en) 2000-01-31
HUP9904026A2 (hu) 2000-05-28
UA64726C2 (uk) 2004-03-15
US20040077730A1 (en) 2004-04-22
NO991358L (no) 1999-03-19
ID18320A (id) 1998-03-26
WO1998011884A1 (en) 1998-03-26
CA2266401A1 (en) 1998-03-26
EP0927028A1 (en) 1999-07-07
BR9711517A (pt) 1999-08-24
ZA978450B (en) 1999-03-19
NO991358D0 (no) 1999-03-19
AU724488B2 (en) 2000-09-21
CZ93699A3 (cs) 1999-08-11
SK31999A3 (en) 1999-12-10
JP2001503737A (ja) 2001-03-21
BG64473B1 (bg) 2005-04-30
US6174925B1 (en) 2001-01-16
US6617360B1 (en) 2003-09-09
CN1237905A (zh) 1999-12-08
BG103277A (en) 2000-01-31
RU2245709C2 (ru) 2005-02-10
NZ334580A (en) 2000-09-29
GB9619757D0 (en) 1996-11-06
HUP9904026A3 (en) 2000-07-28
KR20000048501A (ko) 2000-07-25

Similar Documents

Publication Publication Date Title
IL128850A (en) Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture
US5993653C1 (en) Composition and column used in hplc
AP9801407A0 (en) Substituted 3,5-diphen l-1,2 4-triazoles and their use as pharmaceutical metal chelators
HUP0200709A2 (hu) Dopamin-D,-receptor affinitású triazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0100064A3 (en) Synergetic fungicidal combination comprising amides derivative and chlorothalonil and its use
HUP0000145A3 (en) Betha-sulfonyl hydroxamic acid derivatives with matrix maetalloproteinases inhibitor activity, use thereof and pharmaceutical compositions containing them
HUP0400932A3 (en) Pharmaceutical composition containing nateglinide and another antidiabetic compound, process for its preparation and for use the same
HU9600813D0 (en) Azole derivatives and pharmaceutical composition thereof
HUP0400887A3 (en) Glycopeptide derivatives and pharmaceutical compositions containing the same
HUP0102372A3 (en) Dihydropyrimidines, preparation thereof and pharmaceutical compositions containing the same
IL136251A0 (en) Soft pellet drug composition and methods for the preparation thereof
GB9520584D0 (en) Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
HUP0103265A3 (en) Cyclic prosaposin-derived peptides, pharmaceutical compositions comprising thereof and their use
IL123013A (en) Substituted imidazoles having biphenylsulfonyl substitution, and pharmaceutical compositions comprising them
IL151496A0 (en) Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
HUP0100717A3 (en) Synergetic fungicidal composition comprising amide compound and its use
AU8278498A (en) Combination drug therapies comprising aminoglycoside antibiotics and n,n'-disubstituted guanidines
HUP0003189A2 (en) Pharmaceutical composition comprising fexofenadine and its derivatives
HUP0003063A3 (en) Synergetic fungicidal composition and its use
IL118644A0 (en) N-Ú(1,4-diazabicyclo Ú2.2.2¾ oct-2-yl) methyl¾ benzamide derivatives their preparation and their application in therapeutics
IL118142A (en) Pharmaceutical composition containing tiagabine hydrochloride together with antioxidants and its preparation
HUP0003357A3 (en) Cyclic azapeptides with angiogenic effect, pharmaceutical compositions comprising them, processes for producing thereof and their use
PL349133A1 (en) Benzamide derivatives and drugs containing the same
HUP0002975A3 (en) N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate and pharmaceutical composition containing it
EP0607284A4 (en) THERAPEUTIC AGENT IN HYDROPHILIC MATRIX.

Legal Events

Date Code Title Description
HCA Change of name of proprietor(s) after amalgamation
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees